Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 508.2 DKK -0.74%
Market Cap: 36.3B DKK

Zealand Pharma A/S
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Zealand Pharma A/S
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Zealand Pharma A/S
CSE:ZEAL
Revenue
kr9.2B
CAGR 3-Years
339%
CAGR 5-Years
98%
CAGR 10-Years
79%
Genmab A/S
CSE:GMAB
Revenue
kr3.6B
CAGR 3-Years
28%
CAGR 5-Years
17%
CAGR 10-Years
41%
Ascendis Pharma A/S
NASDAQ:ASND
Revenue
€646.5m
CAGR 3-Years
169%
CAGR 5-Years
135%
CAGR 10-Years
53%
B
Bavarian Nordic A/S
CSE:BAVA
Revenue
kr6.9B
CAGR 3-Years
42%
CAGR 5-Years
29%
CAGR 10-Years
19%
Bioporto A/S
CSE:BIOPOR
Revenue
kr36.6m
CAGR 3-Years
11%
CAGR 5-Years
10%
CAGR 10-Years
6%
Saniona AB
STO:SANION
Revenue
kr743.2m
CAGR 3-Years
268%
CAGR 5-Years
132%
CAGR 10-Years
47%
No Stocks Found

Zealand Pharma A/S
Glance View

Market Cap
35.7B DKK
Industry
Biotechnology

Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.

ZEAL Intrinsic Value
HIDDEN
Show

See Also

What is Zealand Pharma A/S's Revenue?
Revenue
9.2B DKK

Based on the financial report for Sep 30, 2025, Zealand Pharma A/S's Revenue amounts to 9.2B DKK.

What is Zealand Pharma A/S's Revenue growth rate?
Revenue CAGR 10Y
79%

Over the last year, the Revenue growth was 11 810%. The average annual Revenue growth rates for Zealand Pharma A/S have been 339% over the past three years , 98% over the past five years , and 79% over the past ten years .

Back to Top